Abstract Details

Title Schwann Cells Express Melanocortin Receptor Subtypes: Activation by ACTH 1-39 and Alpha-MSH Enhances Proliferation

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P1 - (-)

Poster/Presentation
Number 430

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Robert P. Lisak, MD, FAAN (Wayne State Univ Sch of Med, Dept of Neuro) PRESENTER	Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argnex. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG Consulting. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Third Bridge Consulting. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clearview Consulting. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alivar Therapeutics. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ANI Pharmaceuticals. Dr. Lisak has received personal compensation in the range of $0-$499 for serving as a Consultant for Coleman Research. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunic. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Consulting. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Tedus Consulting. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for COUR Pharma. The institution of Dr. Lisak has received research support from NINDS. The institution of Dr. Lisak has received research support from Argenx. The institution of Dr. Lisak has received research support from Ra Pharmaceuticals. Dr. Lisak has received publishing royalties from a publication relating to health care. Dr. Lisak has received publishing royalties from a publication relating to health care.
	No disclosure on file
	No disclosure on file
	No disclosure on file